Aclaris Therapeutics Names Jesse Hall, M.D., Chief Medical Officer To Strengthen Clinical Leadership

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune-inflammatory diseases, has announced the appointment of Jesse Hall, M.D., as Chief Medical Officer. In this role, Dr. Hall will lead Aclaris’ clinical strategy and guide the development of its portfolio of immuno-inflammatory product candidates. Dr. Hall brings decades of experience in the medical and clinical development fields, particularly in immunology and antibody development. 

His expertise spans all phases of drug development, from early-stage research through global regulatory filings and approvals, Phase IV post-marketing surveillance, and commercial launch support. Most recently, Dr. Hall served as Chief Medical Officer at AltruBio, where he led all clinical and medical functions. Prior to this, he held roles with increasing responsibility at several biopharmaceutical companies, including Sublimity Therapeutics, Ardea Biosciences (a subsidiary of AstraZeneca), Amgen, and Abbott Labs.

Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris, said in a statement, “At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and has the right experience to lead our clinical organization. Jesse’s diverse expertise in clinical development and operations, safety/pharmacovigilance, medical affairs, and regulatory and clinical strategy makes him the ideal leader for our clinical efforts going forward.”

“This is an exciting time to join Aclaris; they are a strong team that prioritizes good science and innovation with a deep and exciting clinical pipeline with important near-term milestones expected and ample cash resources to accomplish their goals. The Company’s portfolio of potential best-in-class biologics and small molecules may help evolve clinical practice and improve the therapeutic experience of patients,” mentioned Dr. Hall. 

Throughout his career, Dr. Hall has been involved in the development and successful launches of key therapeutics, such as the monoclonal antibodies HUMIRA® (adalimumab) and PROLIA® (denosumab). Dr. Hall earned a Bachelor of Arts degree from the University of San Diego and a Doctor of Medicine degree from the University of Oklahoma College of Medicine. He completed his surgical training at the Medical College of Pennsylvania and Hahnemann University. With his extensive background in clinical development, Dr. Hall is well-positioned to drive Aclaris’ clinical strategy and help the company maximize the potential of its immuno-inflammatory therapies.